Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2017-11-16
Target enrollment:
Participant gender:
Summary
This is a non-randomized, multi-dose, first-in-human, multicenter, two arm (Arm A: VGX-100
alone; Arm B: VGX-100 co-administered with bevacizumab), open label, dose escalation study in
subjects with advanced or metastatic solid tumors. The study is aimed at evaluating the
safety and establishing the recommended dose of the VEGF-C human monoclonal antibody VGX-100
when administered alone or in combination with bevacizumab.